The Effect of CXCL12 on Survival Outcomes of Patients with Viral Hepatitis-associated Hepatocellular Carcinoma After Hepatectomy

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 17

PMID 38756575

Authors

Yan Lu

Fei Xing

Songlin Peng

Affiliations

Soon will be listed here.

Abstract

Background: The CXCL12-CXCR4/CXCR7 axis is garnering growing attention. But the comprehension of its function in the progression of HCC remains controversial. The purpose of this study was to investigate the effects of CXCL12 and its receptor on the prognosis of patients with viral hepatitis-associated HCC after hepatectomy.

Methods: A total of 86 patients had been enrolled who had undergone hepatectomy for HCC and followed up to July 31, 2019, and their clinicopathological and follow-up data were recorded. Tumor and peritumoral tissues were obtained to detect the expression of CXCL12, CXCR4, and CXCR7 using immunohistochemistry. Real-time polymerase chain reaction was utilized to detect hepatitis B or C virus loads, while survival analysis was performed using the Kaplan-Meier method. Furthermore, the Cox proportional hazards regression model was employed to analyze the factors affecting the prognosis.

Results: The results revealed that the CXCL12, CXCR4, and CXCR7 expression in tumor tissues was lower than in the corresponding non-tumor tissues in 20.93 %, 22.09 %, and 23.26 % of the patients, respectively, and that only CXCL12 was found to be related to the extrahepatic invasion of HCC. The survival analysis and Cox regression showed that only CXCL12 was associated with the postoperative survival of patients with HCC, and that it was an independent prognostic risk factor in the CXCL12-CXCR4/CXCR7 axis. The CXCL12 group represented shorter progression-free survival and lower overall survival rates. However, the subgroup analysis displayed that the survival difference associated with CXCL12 was only manifested in patients with higher expression of CXCR4 or CXCR7 in HCC, as compared to the surrounding tissues.

Conclusions: Our findings suggest that, when assessing the prognostic significance of CXCL12 in HCC, it is essential to consider the expression level of its receptor. Nevertheless, CXCL12 can potentially serve as a promising prognostic marker for HCC.

References

Liu H, Liu Y, Liu W, Zhang W, Xu J . EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015; 6:8494. PMC: 4598861. DOI: 10.1038/ncomms9494. View

Liepelt A, Tacke F . Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. Am J Physiol Gastrointest Liver Physiol. 2016; 311(2):G203-9. DOI: 10.1152/ajpgi.00193.2016. View

Xiang Z, Zeng Z, Tang Z, Fan J, Sun H, Wu W . Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J. 2009; 15(6):519-25. DOI: 10.1097/PPO.0b013e3181c6aa6b. View

Semaan A, Dietrich D, Bergheim D, Dietrich J, Kalff J, Branchi V . CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Arch. 2016; 470(2):185-196. DOI: 10.1007/s00428-016-2051-5. View

Terada R, Yamamoto K, Hakoda T, Shimada N, Okano N, Baba N . Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest. 2003; 83(5):665-72. DOI: 10.1097/01.lab.0000067498.89585.06. View

Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes H . CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One. 2010; 5(2):e9175. PMC: 2820091. DOI: 10.1371/journal.pone.0009175. View

Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H . Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol. 2008; 5(5):373-8. PMC: 4073694. DOI: 10.1038/cmi.2008.46. View

Hu F, Miao L, Zhao Y, Xiao Y, Xu Q . A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma. Drug Des Devel Ther. 2015; 9:3625-33. PMC: 4507792. DOI: 10.2147/DDDT.S86032. View

Santagata S, Ierano C, Trotta A, Capiluongo A, Auletta F, Guardascione G . CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. Front Oncol. 2021; 11:591386. PMC: 8082172. DOI: 10.3389/fonc.2021.591386. View

10.

Xiang Z, Zeng Z, Tang Z, Fan J, Zhuang P, Liang Y . Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 2009; 9:176. PMC: 2704220. DOI: 10.1186/1471-2407-9-176. View

11.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

12.

Wu Y, Tian L, Xu Y, Zhang M, Xiang S, Zhao J . CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing STAT3. Mol Med Rep. 2018; 18(2):1644-1650. DOI: 10.3892/mmr.2018.9114. View

13.

Costantini S, Raucci R, De Vero T, Castello G, Colonna G . Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Cytokine. 2013; 64(1):316-21. DOI: 10.1016/j.cyto.2013.05.024. View

14.

Zhang B, Zhang B, Zhang Z, Huang Z, Chen Y, Chen M . 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci China Life Sci. 2018; 61(6):660-670. DOI: 10.1007/s11427-017-9259-9. View

15.

Shah S, Greig P, Gallinger S, Cattral M, Dixon E, Kim R . Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006; 202(2):275-83. DOI: 10.1016/j.jamcollsurg.2005.10.005. View

16.

Yang J, Zhang L, Jiang Z, Ge C, Zhao F, Jiang J . TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics. 2019; 9(20):5810-5827. PMC: 6735379. DOI: 10.7150/thno.34973. View

17.

Decaillot F, Kazmi M, Lin Y, Ray-Saha S, Sakmar T, Sachdev P . CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011; 286(37):32188-97. PMC: 3173186. DOI: 10.1074/jbc.M111.277038. View

18.

Luker K, Gupta M, Luker G . Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 2008; 23(3):823-34. PMC: 2653984. DOI: 10.1096/fj.08-116749. View

19.

Xu J, Liang J, Meng Y, Yan J, Yu X, Liu C . Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. Clin Cancer Res. 2017; 23(15):4482-4492. DOI: 10.1158/1078-0432.CCR-16-2131. View

20.

Neve Polimeno M, Ierano C, DAlterio C, Losito N, Napolitano M, Portella L . CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cell Mol Immunol. 2014; 12(4):474-82. PMC: 4496532. DOI: 10.1038/cmi.2014.102. View